argipressin--des-glynh2(9)- and Alzheimer-Disease

argipressin--des-glynh2(9)- has been researched along with Alzheimer-Disease* in 3 studies

Reviews

1 review(s) available for argipressin--des-glynh2(9)- and Alzheimer-Disease

Article	Year
New drug interventions in Alzheimer's disease. Current opinion in neurology and neurosurgery, 1992, Volume: 5, Issue:1 Topics: Aged; Alzheimer Disease; Arginine Vasopressin; Cholinesterase Inhibitors; G(M1) Ganglioside; Humans; Mental Recall; Neuropsychological Tests; Physostigmine; Pilot Projects; Receptors, Cholinergic; Tacrine	1992

Trials

2 trial(s) available for argipressin--des-glynh2(9)- and Alzheimer-Disease

Article	Year
DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial. Neurology, 1990, Volume: 40, Issue:7 We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT. Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arginine Vasopressin; Chi-Square Distribution; Double-Blind Method; Humans; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic	1990
Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia. Neurobiology of aging, 1985,Summer, Volume: 6, Issue:2 Vasopressin peptides have been shown to facilitate learning and memory in both animals and humans; however, the effectiveness in humans is controversial. In a double blind parallel group study, 17 demented subjects (either Alzheimer's or alcoholic) were given either desglycinamide-9-arginine-8-vasopressin (DGAVP) 92 micrograms intranasally TID or an identical placebo for 1 week after having received 1 week of placebo. To our knowledge, this is the first report of DGAVP being used in subjects with dementia. The DGAVP group had a statistically significant improvement on the Buschke list learning of low imagery words. However, for various reasons discussed in the paper, we feel this finding needs to be replicated before any definite conclusions can be drawn. Since there were no other appreciable behavioral effects of this DGAVP regimen, our results should be considered negative. There was no evidence of any DGAVP-related adverse effects, except for possible weight gain. Topics: Affect; Aged; Alcoholism; Alzheimer Disease; Arginine Vasopressin; Clinical Trials as Topic; Dementia; Humans; Learning; Mental Recall; Middle Aged	1985

Article

Year

DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial.

Neurology, 1990, Volume: 40, Issue:7

We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.

Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arginine Vasopressin; Chi-Square Distribution; Double-Blind Method; Humans; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic

1990

Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia.

Neurobiology of aging, 1985,Summer, Volume: 6, Issue:2

Vasopressin peptides have been shown to facilitate learning and memory in both animals and humans; however, the effectiveness in humans is controversial. In a double blind parallel group study, 17 demented subjects (either Alzheimer's or alcoholic) were given either desglycinamide-9-arginine-8-vasopressin (DGAVP) 92 micrograms intranasally TID or an identical placebo for 1 week after having received 1 week of placebo. To our knowledge, this is the first report of DGAVP being used in subjects with dementia. The DGAVP group had a statistically significant improvement on the Buschke list learning of low imagery words. However, for various reasons discussed in the paper, we feel this finding needs to be replicated before any definite conclusions can be drawn. Since there were no other appreciable behavioral effects of this DGAVP regimen, our results should be considered negative. There was no evidence of any DGAVP-related adverse effects, except for possible weight gain.

Topics: Affect; Aged; Alcoholism; Alzheimer Disease; Arginine Vasopressin; Clinical Trials as Topic; Dementia; Humans; Learning; Mental Recall; Middle Aged

1985